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Although whole-parasite vaccine strategies for ma-
laria infection have regained attention, their immuno-
logical mechanisms of action remain unclear. We
find that immunization of mice with a crude blood
stage extract of the malaria parasite Plasmodium
falciparum elicits parasite antigen-specific immune
responses via Toll-like receptor (TLR) 9 and that the
malarial heme-detoxification byproduct, hemozoin
(HZ), but not malarial DNA, produces a potent adju-
vant effect. Malarial and synthetic (s)HZ bound
TLR9 directly to induce conformational changes in
the receptor. The adjuvant effect of sHZ depended
on its method of synthesis and particle size. Although
natural HZ acts as a TLR9 ligand, the adjuvant
effects of synthetic HZ are independent of TLR9 or
the NLRP3-inflammasome but are dependent on
MyD88. The adjuvant function of sHZ was further
validated in a canine antiallergen vaccine model.
Thus, HZ can influence adaptive immune responses
to malaria infection and may have therapeutic value
in vaccine adjuvant development.
INTRODUCTION
Whole-microbe vaccines have been successful in preventing
and/or treating many infectious diseases, by harboring not only
protective antigens, but also ‘‘built-in’’ adjuvant components
capable of activating the innate immune system (Pulendran
and Ahmed, 2006; Ishii et al., 2008; Palm and Medzhitov,
2009). In the case of malaria, there is evidence that host protec-
tive immunity against blood stage malaria parasites can be
achieved in humans as well as in animal models following
whole-parasite vaccinations, although large numbers of para-50 Cell Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Insites are required (Good, 2009; Doolan et al., 2009). Among
parasite-derived molecules, potentially protective antigens
have been investigated intensively for vaccine development
(Girard et al., 2007; Coppel, 2009). However, the adjuvant
components within blood stage parasites have not been
explored; likely adjuvant components include ligands for innate
immune receptors, such as Toll-like receptors (TLRs), NOD-like
receptors (NLRs), and RIG-I-like receptors (Stevenson and Riley,
2004; Coban et al., 2007a).
There are several candidate molecules in Plasmodium para-
sites that could act as adjuvant components (Schofield et al.,
2002; Pichyangkul et al., 2004; Krishnegowda et al., 2005;
Coban et al., 2005; Parroche et al., 2007; Seixas et al., 2009).
TLR2 and TLR9 have been shown to mediate innate immune
system activation by GPI, a heat-labile fraction, and hemozoin
(HZ) and DNA derived from Plasmodium falciparum (Pf) (Krishne-
gowda et al., 2005; Pichyangkul et al., 2004; Coban et al., 2005;
Parroche et al., 2007); however, discrepancies among these
findings remain unresolved (Coban et al., 2007a). TLR9 has
also been proposed to play important roles in the pathogenesis
of cerebral malaria by recruiting immune cells into the brain
(Coban et al., 2007b; Griffith et al., 2007), or in that of severe ma-
laria owing to the induction of regulatory T cells and/or synergy
with interferon g (IFNg) signaling (Hisaeda et al., 2008; Franklin
et al., 2009), but this is also controversial with some reports sug-
gesting that this is not the case (Lepenies et al., 2008; Togbe
et al., 2007). In addition, recent reports suggest that uric acid
is released during malaria infection (Orengo et al., 2008), thereby
activating the innate immune system presumably via NLRs,
particularly NLRP3 (also known as NALP3) and its adaptor mole-
cule apoptosis-associated speck-like protein containing
a CARD domain (ASC), leading to caspase-1 activation (Franchi
et al., 2009).
We therefore investigated further whether TLRs, and TLR9 in
particular, as well as other innate immune receptors such as
NLRs, are involved in Pf-mediated innate and adaptive immune
responses, and whether HZ plays any role in such adaptive
immune responses. We found that Pf whole-parasite crudec.
Figure 1. Pf Crude Extract Contains an Adjuvant Element for Coadministered Malaria Antigens in a TLR9-Dependent Manner
(A–C) Serum anti-Pf crude extract-specific IgG (A) and IgG2c antibody responses (B) and IFNg from cultured spleen cells (C) were measured by ELISA at 3 weeks
after the intraperitoneal immunizations with Pf crude extract. See also Figure S1.
(D and E) Serum anti-Pf crude extract-IgG antibody responses of Nlrp3/ and Asc/ mice. (E) shows levels only after prime immunization.
(F) Sera from WT and Tlr9/ mice were analyzed for anti-Pf SERA5-specific IgG responses. The results shown are representative of at least two independent
experiments with three to five mice per group. (*p < 0.05; mean levels of serum antibodies ± standard deviation [SD]).
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TLR9 Binds Hemozoin via a Cysteine Residueextracts elicit parasite antigen-specific adaptive immune
responses via TLR9, but not via NLRP3 or ASC. The malarial
product HZ showed a potent adjuvant effect without any require-
ment for DNA. Further analysis at the molecular and atomic
levels revealed that TLR9 binds to HZ directly and specifically,
in a manner that depends on particular motifs and amino acid
sequences, similar to its binding of CpG DNA, a well-known
TLR9 ligand. A synthetic version of HZ also displayed a strong
adjuvant effect; however, its optimal response was quite variable
and dependent on its method of synthesis as well as its structural
appearance.
RESULTS
A Pf Crude Extract Contains a TLR9 Ligand as a Built-in
Adjuvant for Coadministered Malaria Antigens
To examine the possible adjuvant effects of whole parasites, we
prepared a large quantity of whole-parasite antigens by freeze-
thawing of Pf-infected red blood cells. The resulting extract,
designated the Pf crude extract, contained products from both
parasites and host red blood cells was immunized into mice.
Three weeks after immunization, without any additional adjuvant,
a significantly higher titer of serum Pf crude extract-specific
immunoglobin G (IgG) was detected compared with the titers
in naive mice and mice immunized with a normal red blood cellCellextract, in a dose-dependent manner (Figure 1A and data not
shown). The antibody titers were 10 times higher after boost
immunizations (Figure 1D).
We subsequently examined whether the immunogenicity of
the whole-parasite vaccine was altered in the absence of
TLR9, because TLR9 has been shown to mediate innate immune
system activation by a heat-labile fraction, HZ and DNA derived
from Pf (Coban et al., 2007a). Accordingly, mice lacking TLR9
showed significantly lower serum IgG (mainly IgG2c) responses
and T-cell-specific IFNg levels than wild-type mice (Figures 1A–
1C). This TLR9-dependent adjuvant effect of whole-parasite
antigens was specific for the immunizing Pf antigens, such as
Pf SERA5 and Pf MSP1 (Figure 1F and data not shown). TLR9-
dependent IgG responses were also observed for IgG2b and
IgG3, but not for IgG1 (see Figures S1A–S1C available online).
These data clearly demonstrate that Pf crude extract possesses
a TLR9 ligand as a built-in adjuvant for coadministered malaria
antigens.
The ASC-Inflammasome Is Not Involved in the Adjuvant
Effect of Pf Crude Extract
We next investigated whether the inflammasome and its compo-
nents were involved, given the fact that Plasmodium parasites
grown in erythrocytes increase the concentration of uric acid,
a known NLRP3 ligand that acts as a ‘‘danger signal’’ andHost & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inc. 51
Figure 2. Malarial DNA Has No Role in the Adjuvanticity of Pf Crude Extract
(A) Serum anti-Pf crude extract-specific IgG antibody responses after immunization with DNase-I-treated and DNase-I-untreated Pf crude extracts. (n = 5 mice
per group; mean ± SD). See also Figure S2B.
(B) Specific binding of rTLR2 or rTLR9 proteins to the coated Pf crude extract measured by ELISA. See also Figure S2A.
(C and D) Specific binding of rTLR9 protein to the coated DNase-I-treated or DNase-I-untreated Pf crude extract (C), or, to Pf DNA or DNase-I-treated PfDNA (D).
See also Figure S2B.
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TLR9 Binds Hemozoin via a Cysteine Residueactivates the ASC-inflammasome (Orengo et al., 2008). More-
over, recent studies suggest that DNA from any living organism
may activate the ASC-inflammasome, independently of TLR9
(Muruve et al., 2008; Takeshita and Ishii, 2008), and that this
may be mediated by AIM2 (Roberts et al., 2009; Hornung
et al., 2009; Fernandes-Alnemri et al., 2009; Burckstummer
et al., 2009). However, neither ASC- nor NLRP3-deficient mice
showed any reduction in the adjuvant effect of Pf crude extract
(Figures 1D and 1E). These data suggest that the critical adjuvant
activity within Pf crude extract is mediated by TLR9, but not
ASC-inflammasome.Pf DNA Is Not Involved in the Adjuvant Effect
of Pf Crude Extract
What components of the malaria parasite are responsible for the
TLR9-dependent adjuvant effect? Although immune recognition
of malarial HZ by TLR9 has been previously demonstrated
in vitro and in vivo (Coban et al., 2005), another study suggested
that HZ itself was immunologically inert, and that TLR9-depen-
dent immune activation is instead caused by HZ-conjugated ma-
larial DNA (Parroche et al., 2007). To investigate whether Plas-
modium DNA is responsible for the TLR9-dependent adjuvant
effect of Pf crude extract, DNA was removed by DNase-I treat-
ment. To confirm that DNA was successfully removed from Pf
crude extract, we performed Pf typing polymerase chain reac-
tion (PCR) based on the nested PCR technique (Snounou
et al., 1993), and did not find a trace of PfDNA after DNase-
treatment (Figure S2B). After immunizations, we found that the
TLR9-dependent adjuvant effect of whole-parasite antigens
was not affected by DNase-I treatment (Figure 2A), suggesting
that DNA is not the TLR9-dependent adjuvant component of
Pf crude extract.
A ligand is defined as a molecule with affinity and specificity for
binding directly to a receptor. To examine such direct interac-
tions between TLR9 and Pf crude extract, we established an
enzyme-linked immunosorbent assay (ELISA)-based binding
assay. Both rTLR9 and rTLR2 showed specific interactions
with their cognate ligands (Figure S2A), confirming previous find-
ings (Rutz et al., 2004). When the Pf crude extract was tested for52 Cell Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inbinding to rTLR9 and rTLR2, we found that TLR9, and to a lesser
extent TLR2, interacted strongly and in a dose-dependent
manner with the Pf crude extract (Figure 2B), consistent with
the findings of a previous report (Parroche et al., 2007). However,
in sharp contrast with their findings, DNase-I treatment of the
Pf crude extract did not alter its interaction with rTLR9, while
the same DNase-I treatment abrogated TLR9 binding to Pf
genomic DNA (Figures 2C and 2D). Of note, in contrast to the
findings of Parroche et al., several attempts using nuclease treat-
ment of Pf crude extract with several nuclease sources, showed
either no effect on Pf crude extract binding to TLR9 or even
nonspecific binding to TLR9 protein (Figures S2B and data not
shown). Taken together, these data clearly demonstrate that
some component of the Pf crude extract acts as a TLR9 ligand,
mediates adaptive immune responses through TLR9, and
directly binds to rTLR9 in a specific manner, and that this inter-
action does not require or involve DNA.Hemozoin Binds Specifically to and Changes the
Conformation of TLR9
After eliminating the possible involvement of genomic DNA in Pf
crude extract adjuvanticity, we next investigated the role of he-
mozoin as a possible adjuvant molecule in the Pf crude extract.
Given that it is not possible to deplete hemozoin from Pf crude
extract without denaturing the malarial antigens (Figure S2C),
and that using extensively purified natural PfHZ would always
be questioned on the basis of its purity, we used synthetic hemo-
zoin derived from a highly pure source and thought to be iden-
tical to natural HZ (Pagola et al., 2000). Competition assays
were then performed to investigate whether sHZ could block
the binding of TLR9 protein to Pf crude extract. TLR9 binding
to the coated Pf crude extract was measured in the presence
of sHZ, CpG DNA (another known TLR9 ligand) or monosodium
urate crystals (MSU). MSU crystals are insoluble immunostimu-
latory crystals that activate the innate immune system in a TLR9-
independent manner (Martinon et al., 2006), because they form
crystals that resemble sHZ in size and rod shape by surface
electron microscopy (Figure S2E). TLR9 binding to the Pf crude
extract was blocked by sHZ in a dose-dependent manner, asc.
Figure 3. Synthetic Hemozoin Competes with Pf Crude Extract or CpG DNA for Binding to rTLR9 Protein
(A–C) Specific competition between the Pf crude extract and sHZ (A), CpG DNA (B) or MSU (C) was measured by ELISA.
(D–F) Conformational changes of rTLR9 protein were measured by CD in the presence and absence of sHZ (D), CpG DNA (E), or MSU (F). See also Figures S2C
and S2F. All experiments were repeated at least five times with similar results.
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did not alter the binding of TLR9 to Pf crude extract (Figure 3C).
Latz et al. recently demonstrated that TLR9 protein changes its
conformation upon ligation (Latz et al., 2007). To monitor the
conformational changes in the rTLR9 protein accompanying
binding of its ligands, circular dichroism (CD) measurements
were performed. Specifically, the CD spectra of rTLR9 protein
were measured with or without the ligands at pH 5.5. The CD
spectra of rTLR9 were altered by CpG DNA and sHZ, but notCellMSU, in a dose-dependent manner, characterized by remark-
able spectral changes with shifts of the zero crossing point
(Figures 3D–3F and Figure S2C). We also performed similar
studies with soluble hemin that showed similar pattern and
changed the conformation of rTLR9 as sHZ did, but not synthetic
dsRNA (poly I:C) (Figure S2F). Taken together, these results
demonstrate that sHZ can compete with Pf crude extract for
binding to rTLR9 and change its conformation in a similar manner
to CpG DNA.Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inc. 53
Figure 4. Peptide Regions in the Human TLR9 Sequence that Bind to Pf Crude Extract, Hemin, and CpG DNA
(A) Peptide sequences that are specific to human TLR9 extracellular domain and their binding to Pf crude extract, hemin and CpG DNA are investigated by ELISA.
(B) Binding of the peptides in which CysXXCys and Cys were respectively replaced with SerXXSer and Ser, as investigated by ELISA. Cys residues are labeled
red, Ser residues are green.
(C and D) Interaction of the peptide VGGNCRRCDH and its mutant to various concentrations of hemin (C) or CpG DNA (D), as investigated by NMR titration. See
also Figure S3. One-dimensional 1H spectra of the peptides were obtained upon the addition of hemin or CpG DNA, and they are shown overlapped.
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TLR9 Observed at the Molecular and Atomic Levels
To further clarify the nature of the interaction between TLR9 and
HZ, short peptides containing unique sequences of the TLR9
extracellular domain (sequences that are specific to the TLR9
extracellular domain and not contained in the extracellular
domains of the other TLR family proteins) were synthesized
and screened to identify the binding site(s) for TLR9 ligands.
The peptides were subjected to ELISA-based binding assays
with various TLR9 ligands, namely, Pf crude extract, hemin
(a single unit of HZ) and CpG DNA (Figure 4A). Only four
peptides, all of which had unique CysXXCys or Cys motifs similar
to zinc finger motifs, bound to these ligands. Cysteine was
required for the binding of these peptides as revealed by the
same assays using mutant peptides (in which Cys was mutated
to Ser) for which the binding ability was completely abrogated
(Figure 4B). To analyze the binding sites in the peptides at an
atomic level, nuclear magnetic resonance (NMR) titration was54 Cell Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inperformed with peptides and CpG DNA and hemin. Using the
peptide VGGNCRRCDH, which had the highest binding to the
TLR9 ligands (Figure 4A), and its mutant peptide, the concentra-
tion of hemin and CpG DNA was increased stepwise and the
spectral changes caused by hemin and CpG DNA were followed
for each, as shown in Figures S3A and S3B and in greater detail
in Figures 4C and 4D. Both hemin and CpG DNA shifted a peak at
a 1H resonance frequency of 8.2 ppm and slightly shifted at 7.1
and 7.8 ppm; all peaks were broadened to a lower intensity,
upon addition of increasing concentrations of hemin, although
no significant broadening was observed for CpG DNA (Figures
4C and 4D). When we performed the same titration experiments
using the mutant peptides that lack Cys, we observed no such
shifts (Figures 4C and 4D), although a decrease in intensity still
remained upon increasing the concentration of hemin. These
results indicate that TLR9 binds both HZ and CpG DNA and
suggest that 4 cysteine residues may play an important role in
the interaction between TLR9 and its ligands.c.
Figure 5. Adjuvanticity of Synthetic Hemozoin Crystals Depends on Their Size, with Smaller Crystals Showing a Better Adjuvant Effect
(A and B) FESEM images of sHZ synthesized by two different methods as described in Experimental Procedures. Scale bars, 500 nm.
(C) Serum OVA-specific IgG responses of C57B/6 mice s.c. immunized with OVA with or without sHZ purified by method 1 or method 2. See also Figure S4A–S4C.
(D) sHZ crystals produced by method 1 were size-differentiated using a laser-scattering particle size distribution analyzer.
(E) Mice were immunized to analyze the adjuvant effects of different sizes of sHZ (50–200 nm and 2–20 mm) and hemin (<50 nm). See also Figure S7. Results are
representative of at least two independent experiments (mean ± SD; n = 3–5 mice per group).
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Adjuvanticity Depends on Its Size
Is pure synthetic HZ a good adjuvant in vivo? Given the fact that
various hemin chloride sources and methods can be used to
synthesize sHZ, we first employed several production protocols
to investigate the adjuvant properties of sHZ (Egan, 2008) using
ultrapure hemin chloride. We found that two commonly used
methods for synthesizing sHZ from hemin chloride produced
crystals with a distinct appearance that differed in their adjuvant
effects. With one method, HZ polymerized in the presence of
acetic acid (method 1) and produced crystals that ranged in
diameter from 50 nm to 1 mm, while the other method, involving
an organic base (method 2), produced crystals that ranged in
size from 1 to 5 mm as visualized by field emission scanning elec-
tron microscopy (FESEM) (Figures 5A and 5B). When mice were
immunized with the model protein antigens ovalbumin (OVA) (or
in some cases human serum albumin [HSA]) in the presence or
absence of sHZ produced by method 1 or 2, the OVA-specific
total IgG responses were significantly higher with sHZ produced
by method 1 than with sHZ produced by method 2 (Figure 5C).
Interestingly, when we separated the HZ produced by method
1 into two size distributions using a laser-scattering particle
size distribution analyzer (Figure 5D), larger sHZ particles (up
to 20 mm in size) were counted. It should be noted that sHZ crys-
tals tend to make aggregates that the larger HZ particles might
be attributed to the aggregation. Nevertheless, sHZ with sizes
between 50 and 200 nm had optimal adjuvant effects compared
with larger sHZ molecules (2–20 mm) and the smaller hemin
monomer (<50 nm) (Figure 5E). We also examined different
administration routes to investigate the adjuvant effects of sHZCellsuch as subcutaneous (s.c.) and intranasal (i.n.) routes, and
found that antigen-specific antibody responses were induced
in a dose-dependent manner (Figures S4A and S4B and Fig-
ure 6A). There were no detectable OVA-specific IFNg or inter-
leukin (IL)-17 production by spleen cells, but substantial
amounts of OVA-specific IL-13 and IL-5 were detected (Fig-
ure S4C). Analysis of the IgG isotypes elevated by sHZ
coadministration showed that mainly IgG1 isotypes were
elevated, followed by IgG2b and IgG2c, in mice (Figure 6B);
this response was very potent when compared with those
elicited by the adjuvants alum or CpG DNA (Figure 6C). On the
other hand, sHZ administration elevated mainly IgG1 responses,
while CpG DNA elevated mainly IgG2a (Figure S4D). Therefore,
sHZ is indeed a potent adjuvant for protein vaccines, with
optimal sizes of 20–200 nm, which coincide with the sizes of
other particle adjuvants taken up by antigen-presenting cells
via receptor-mediated endocytosis (McGee et al., 1997; Xiang
et al., 2006).
Synthetic Hemozoin’s Adjuvant Effect Is Mediated by
MyD88, but Not TLR9 or the Inflammasome/IL-1b
We further investigated how the HZ adjuvant effect was regu-
lated. To examine whether the potent adjuvant effect of sHZ
was mediated by TLR9 and through MyD88, mice lacking
TLR9 and MyD88 were immunized with OVA plus sHZ. MyD88-
deficient mice failed to elicit a serum anti-OVA antibody titer
(Figure 6D). By contrast, however, TLR9-deficient mice showed
comparable anti-OVA titers to those in wild-type mice, suggest-
ing that there are distinct mechanisms for the adjuvant effects
of sHZ other than TLR9, any of which seem to culminate inHost & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inc. 55
Figure 6. Synthetic Hemozoin’s Potent Adjuvant Effect Is Mediated by MyD88 but Independently of TLR9 and the Inflammasome
(A and B) Mice were immunized with HSA and various concentrations of sHZ. Serum HSA-specific IgG (A) and IgG isotypes (B) were measured by ELISA
(mean ± SD).
(C) Comparison of the adjuvant effects of alum, CpG DNA, and sHZ. Balb/c mice were immunized s.c. with OVA and alum (200 mg), CpG DNA (50 mg), and sHZ
(800 mg), and serum OVA-specific IgG responses were determined after boost immunizations by ELISA (mean ± standard error; n = 3). *p < 0.05 compared with
OVA-alone group. See also Figure S4D.
(D–F) Serum OVA-specific IgG responses of Myd88/ and Tlr9/ mice (D), Nlrp3/ and Asc/ mice (E), and IL1R/ mice (F) after boost immunizations were
determined by ELISA (**p < 0.01; mean ± SD). Wild-type (n = 5–6); Myd88/ (n = 6); TLR9/ (n = 6); Nlrp3/ (n = 3); Asc/ (n = 6) and IL1R/ (n = 5). See also
Figures S5A–S5C and Figure S6. Experiments are representative of at least two independent experiments.
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taining similar results with HSA (Figures S5A and S5B).
Particles like MSU crystals have recently been shown to be
recognized by NOD-like receptors (NLRP3 in the case of MSU)
and form large cytosolic complexes, collectively called the in-
flammasome. We were interested in clarifying whether the
adjuvanticity of sHZ, whose appearance resembles MSU
crystals (Figure 5A and Figure S2D), could involve the inflamma-
some. In the same set of OVA or HSA immunization protocols,
mice deficient in ASC or NLRP3 elicited normal antibody
responses (Figure 6E and Figure S5B) as well as IL1R-deficient
mice (Figure 6F and Figure S5C). These results suggest that
inflammasome/ IL-1b pathway have a minimal role in the
adjuvant effect of sHZ.
To examine whether sHZ-induced inflammation occurs in vivo,
we measured neutrophil recruitment. When sHZ was injected
intraperitoneally, significant numbers of neutrophils were re-
cruited into the peritoneum within 24 hr (Figure S6A), and the
neutrophil recruitment occurred normally in mice lacking either
ASC or TLR9 (Figure S6B). However, mice lacking MyD88 failed
to exhibit neutrophil recruitment in response to sHZ injection
(Figure S6A).56 Cell Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier InSynthetic Hemozoin Is a Potent Adjuvant for Malarial
Antigens as Well as for an Allergen
It has been previously shown that subclinical infection of healthy
human volunteers with red cells infected with Pf or immunization
of mice with a small number of dead parasites in the presence of
CpG DNA or alum can induce cellular immunity and protection
(Pombo et al., 2002; Good, 2009). To examine whether sHZ
would have a potent adjuvant effect on immunization with Pf
crude extract from a few parasites, we immunized mice s.c.
with 10 mg total Pf crude extract together with sHZ, boosted
twice, and measured anti-Pf crude extract specific antibody
responses. sHZ significantly improved IgG levels (mainly IgG2c
and IgG1) against Pf crude extract (Figure 7A and data not
shown).
To examine whether sHZ could be used in animal species
other than mice, we immunized Beagle dogs with house dust
mite allergen (Derf2) together with alum and sHZ, and boosted
that elevated IgG2 type (but not IgG1) antibodies, which may
resemble Th1-like immune responses in dogs (Figure 7B and
7C) (Hou et al., 2006). Accordingly, Derf2-specific IgE responses
after Ag challenges were significantly reduced in sHZ coadminis-
tered dogs (Figure 7C). It is of note, however, that antibodyc.
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which was different from those in dogs (Figure S5D). These
data further suggest that sHZ may serve as a potent Th1-like
adjuvant, at least in the canine model, while it acts like a
Th2-dominant adjuvant in a murine model.
DISCUSSION
Malaria is still one of the leading pathogens, affecting 40% of the
world’s population and killing over one million people each year,
but a successful vaccine against it not yet available. Owing to the
failure of many clinical trials for recombinant vaccines, and
recent progress in our understanding of innate immune adjuvant
effect of microbial products (Kaisho and Akira, 2002), the whole-
parasite vaccine strategy has been regaining attention (Good,
2009; Doolan et al., 2009). Successful vaccination with erythro-
cytic parasites was achieved using powerful adjuvants,
such as CpG DNA (Su et al., 2003). We further demonstrated
that an increased dose of a crude extract of Pf parasites without
adjuvant successfully displayed strong immunogenicity, owing
to the enhanced ‘‘built-in adjuvant’’ activity of the parasite.
Surprisingly, this adjuvant effect was heavily dependent on
TLR9. Because this has been a matter of controversy, the
TLR9 ligand in malaria parasite was carefully analyzed again,
and we found that DNA is not required for this TLR9-mediated
adjuvant effect of thePf crude extract (Figure 2). It is thus reason-
able to interpret that the built-in adjuvant in Pf crude extract is
a non-DNA TLR9 ligand, such as HZ and/or some other heat-
labile components as previously reported (Coban et al., 2005;
Pichyangkul et al., 2004).
HZ is a heme crystalline dimer generated by parasite digestion
of hemoglobin as a byproduct of the heme detoxification system
in malaria infection (Arese and Schwarzer, 1997; Hanscheid
et al., 2007). It has been proposed to play important roles in path-
ophysiology during malaria infection, because it activates
macrophages and dendritic cells to produce both proinflamma-
tory and anti-inflammatory cytokines and chemokines (Eng-
werda and Good, 2005; Keller et al., 2006; Hanscheid et al.,
2007; Coban et al., 2007a). Although immune recognition of
malarial HZ by TLR9 has been demonstrated in vitro and
in vivo (Coban et al., 2005), another study suggested that HZ
itself was immunologically inert, and that TLR9-dependent
immune activation is instead caused by HZ-conjugated malarial
DNA (Parroche et al., 2007).
Parroche et al. suggested that DNase-I treatment of Pf crude
extract did not remove Plasmodium DNA from PfHZ shown by
Pf-specific PCR (Parroche et al., 2007). When we performed
PCR by using the same Pf-specific primers, 205 bp PCR product
of Pf DNA was completely lost after DNase-I treatment
(Figure S2B). We further confirmed the absence of Pf DNA after
treatment of Pf crude extract by PCR using the other primers
(101 bp product) (data not shown). In vivo, this DNase-free Pf
crude extract displayed potent adjuvant activity via TLR9
(Figure 2A), strongly suggesting that the built-in adjuvant of
Pf crude extract is not DNA.
What in Pf crude extract would be a TLR9 ligand rather than Pf
DNA? We went on to reconfirm our previous finding that HZ is
a TLR9 ligand by examining the definition of a ligand for
a receptor, in which a ligand is to directly bind to a receptor inCella specific manner. TLR9 binds directly both HZ and hemin,
and change its conformation following binding to HZ (Figure 3).
Moreover, competition for TLR9 binding occurs among Pf crude
extract, CpG DNA, and sHZ, further supporting the possibility
that HZ fulfills the definition of TLR9 ligand specificity. We also
identified the binding motifs in the extracellular domain of
TLR9, where cysteine residues play a crucial role in controlling
the binding to ligands including Pf crude extract, heme, and
CpG DNA (Figure 4). Taken together, these findings suggest
that the adjuvant component of erythrocytic stage Pf parasites
contains a TLR9 ligand, most likely HZ, but not DNA.
Involvement of the inflammasome pathways in inflammation
during malaria infection, as has been implicated by a recent
report (Orengo et al., 2008), was not apparent in the built-in adju-
vant effect of whole-parasite vaccination with erythrocytic stage
Pf crude extract (Figure 1). Consistently, the effect of synthetic
HZ was also independent of the NLRP3-ASC inflammasome,
as well as IL-1 receptor. It is of note that, while natural HZ in
the Pf crude extract acts mostly as a TLR9 ligand, sHZ has an
adjuvant effect independent of TLR9, but still utilizes the
MyD88-dependent pathway. One possible explanation for this
difference is that the uptake or ability to break the integrity of
phagosomal and/or endosomal membrane of natural and
synthetic HZ might differ given that the natural HZ is often
covered by Pf-derived lipid, protein, or nucleic acids, compared
with sHZ as a naked sharp crystal. Another explanation is that,
although natural HZ purified fromPf cultures is known to be iden-
tical to sHZ (Pagola et al., 2000), several purification protocols
give different crystal sizes ranging from 50 nm to 20 mm, which
displayed quite different adjuvant activities (Figure 5). The
studies are under investigation to examine whether different
sizes of sHZ make distinct delivery and interaction with the
innate immune cells and their immune receptors.
In addition, recent reports have suggested that immune recog-
nition of and inflammatory response by sHZ is mediated by
NLRP3 (Dostert et al., 2009; Griffith et al., 2009; Jaramillo
et al., 2009). Although all of these three reports showed that
IL-1b production by macrophages as well as neutrophil recruit-
ment in response to sHZ was reduced in mice lacking NLRP3,
precise mechanism of NLRP3-inflammasome activation are yet
unclear. Griffith et al. suggested that uric acid is induced by
sHZ and that the uric acid is the NLRP3 ligand (Griffith et al.,
2009), but Dostert et al. suggested that uric acid is not involved
in NLRP3 activation by sHZ (Dostert et al., 2009). Moreover, Jar-
amillo et al. showed elegantly that sHZ activates Lyn/Syk-medi-
ated intracellular signaling pathway at the upstream of NLRP3 or
ASC, indicating the existence of other HZ receptor(s) such as
Dectin1, TREM family members, Siglec, or DAP12 (Jaramillo
et al., 2009). Although the involvement of NLRP3 in sHZ-induced
IL-1b or the following inflammatory response may play an impor-
tant role in pathogenesis of malaria infections, we clearly demon-
strate that NLRP3 as well as ASC, IL-1 receptor is not involved in
sHZ-adjuvant activity (Figure 6), suggesting that there may be
additional receptor(s) as well as pathway(s) for HZ-induced
innate and adaptive immune activations.
Finally we found that sHZ acts as a potent adjuvant only when
its synthesis method and size were optimized (Figure 5). This
adjuvant effect of HZ for protein vaccines was observed with
different model antigens, such as OVA and HSA, and via differentHost & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inc. 57
Figure 7. Synthetic Hemozoin Could Be Used as Adjuvant for Whole-Blood Malaria Antigens and Against Canine Allergy
(A) WT mice were immunized s.c. with 10 mg Pf crude extract and sHZ and were boosted twice. Serum Pf crude extract-specific IgG responses were analyzed by
ELISA (mean ± SD; n = 4 per group).
(B and C) ELISA serum anti-Derf2-specific IgG2, IgG1 (B), and IgE (C) responses of Beagle dogs immunized with Derf2 antigen formulated with or without alum
and alum + sHZ. See also Figure S5D. Experiments were repeated twice using four animals per group (**p < 0.01).
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note that unlike CpG DNA, which has species-specific activity,
HZ displayed its adjuvant effect in several animal models for
vaccines, including murine, canine and non-human primate
models (Figures 5–7, data not shown). In mice, a predominantly
IgG1-dominant antibody adjuvant effect observed after HZ-ad-
juvanted immunization and T cell specific immune responses
were mainly IL-13 and IL-5, but not IFNg or IL-17, suggesting
that HZ elicits Th2-type immune responses in mice (Figures 5,
6, and S4). However, by contrast, dog immunization with HZ eli-
cited IgG2-dominant antibody responses, which is considered
a Th1-type immune response (Reed and Scott, 1993). sHZ
administration in the dog-allergy model was nonetheless very
potent to reduce allergen-specific IgE responses (Figure 7), sug-
gesting successful usage of sHZ as an adjuvant in dogs against
allergy. Similarly, our data suggested that sHZ could be intro-
duced externally as an adjuvant to improve immunogenicity of
whole-malaria vaccines (Figure 7A). Our preliminary data also
suggest that, in non-human primates, sHZ could elevate malarial
antigen-specific B and T cell responses, and could be used as
a vaccine adjuvant for whole-blood stage vaccines (K.J.I.,
unpublished data). Overall, our results clearly show that HZ
possesses inflammatory and adjuvant activities through differ-
ential regulation by TLR9 pathways, thereby potentiating its
ability to act as a therapeutic target for treating malaria infection,
and its usefulness in vaccine adjuvant development.
EXPERIMENTAL PROCEDURES
Reagents
Hemin chloride was from Fluka (HPLC purified, >98% pure), whereas OVA and
HSA (low endotoxin) were from Sigma. A synthetic CpG DNA (D35) was from
Gene Design Incorporation. DNase-I was from Invitrogen. Zymosan was
from Invivogen. MSU crystals were prepared as described elsewhere (Marti-
non et al., 2006).
Mice and Immunizations
Mice deficient for MyD88, TLR9, Asc or Nlrp3, and Asc on a C57BL/6 back-
ground were generated and used for experiments as described previously
(Coban et al., 2005; Franchi and Nunez, 2008). All animal experiments were58 Cell Host & Microbe 7, 50–61, January 21, 2010 ª2010 Elsevier Inperformed according to the institutional guidelines approved by the Research
Institute for Microbial Diseases and Immunology Frontier Research Center of
Osaka University and the University of Michigan.
Wild-type and Tlr9/ mice were immunized intraperitoneally with the Pf
crude extract (100 ml, approximately 1 3 108 parasites). Alternatively, mice
were immunized with a DNase-I-treated Pf crude extract. At 3 weeks after
immunization, antibodies against Pf crude extract antigens in the sera of
mice were detected by ELISA.
Various immunization schedules were conducted using either OVA or HSA
as antigens. For s.c. immunizations, mice were injected on day 0 with 50 mg
OVA (or 10 mg HSA) in a total of 200 ml sHZ solution at various concentrations
and boosted on day 10 with 25 mg OVA (or 10 mg HSA) in the same sHZ
solution. Blood samples were collected from the mice on day 17 for analysis
of OVA- or HSA-specific antibody responses. For i.n. immunizations, mice
were anesthetized and administered i.n. with 5 mg OVA with or without 80 mg
sHZ (15 ml/nose), twice, at 2-week intervals. The mice were sacrificed
10 days after the boost, and serum, bronchoalveolar lavage fluid, and nasal
fluid secretion samples were collected for antibody measurements.
Dogs and Allergy Model
Five-month-old Beagle dogs from the breeding colony at Zenoaq Animal
Experiment Center (Nippon Zenyaku Kogyo Co., Ltd., Fukushima, Japan)
were used. All immunization and sensitization protocols were performed in
accordance with the institutional guidelines of and approved by Zenoaq
Animal Center Laboratories Committee. Dogs were immunized s.c. on day
0 with 100 mg Derf2 protein produced in silkworms by a recombinant Baculo-
virus system, formulated in 500 mg aluminum hydroxide in a 200 mg sHZ solu-
tion, and boosted on day 14 with the same dose. Four weeks after the boost
immunization, dogs were challenged with Derf2 s.c. four times biweekly. Blood
samples were collected on days 7, 14, 21, and 28 for analysis of Derf2-specific
IgG1 and IgG2 antibody responses, and on day 90 for the measurement of
antigen-specific IgE responses.
Preparation of Pf Crude Extract, Natural HZ, Synthetic HZ,
and Pf DNA
Mycoplasma-free Pf parasites (3D7) were maintained in culture medium as
described previously (Aoki et al., 2002). After synchronization, mature and
HZ-rich mostly trophozoite and schizont stage parasites (4%–5%) were puri-
fied by 63% Percoll density centrifugation, washed and resuspended in
incomplete medium, freeze-thawed three or four times, and stored at 80C
until use. Each milliliter of HZ-rich Pf crude extract preparation contained
approximately 1 3 109 infected erythrocytes. As controls, uninfected human
erythrocytes were treated similarly. Pure natural HZ was extensively purified
from Pf-infected erythrocytes as described previously (Coban et al., 2005).c.
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2008). Method 1 (acid-catalyzed method) is known to produce smaller and
homogenous crystals and was performed as previously described (Coban
et al., 2005; Jaramillo et al., 2005). Briefly, 45 mg hemin chloride was dissolved
in 4.5 ml 1 N NaOH and neutralized with 1 N HCl. Then, acetic acid was added
until the pH reached 4.8, at a constant temperature of 60C with magnetic stir-
ring. The mixture was allowed to precipitate at room temperature overnight.
The precipitate was subjected to washes with 2% SDS-buffered with 0.1 M
sodium bicarbonate (pH 9.1) and subsequent extensive washes with 2%
SDS, and then six to eight washes with distilled water. Method 2 (anhydrous
method in methanol) is known to produce much bigger crystals and was per-
formed as previously described (Bohle et al., 2002). Briefly, hemin chloride
(52.2 mg) was dissolved completely in 2 ml 2,6-lutidine L, diluted with 10 ml
dimethyl sulfoxide:methanol (1:1 mixture), tightly wrapped with parafilm and
left at room temperature for 2 weeks in the dark, before being centrifuged
and washed with 10 ml 0.1 M NaHCO3 for 3 hr. The final product was washed
three times with water and methanol, and dried. A stock solution in distilled
water was prepared for use in in vivo studies and stored at 4C. The HZ
concentration was calculated as either mM or mg/ml after weighing the dried
amount of sHZ. Experiments were mostly performed with sHZ prepared by
method 1, except for the results shown in Figure 5B. All solutions were
prepared and resuspended in endotoxin-free water (double-processed tissue
culture water, Sigma-W3500) and stored in the dark at 4C. There was no
detectable level of endotoxin by LAL assay in any HZ preparation. None of
the sHZ purified had any other contaminants, such as hemin, as determined
by TLC (Figure S7A) or protein/DNA determined by SDS-PAGE at pH 11 and
agarose gel, respectively (data not shown). FT-IR and powder X-ray diffraction
pattern of the sHZ confirmed that the sample showed the same unit cell
parameters as reported previously (Pagola et al., 2000) (Figures S7B and
S7C). Pf genomic DNA was isolated as reported previously (Kongkasuriyachai
et al., 2004).
Recombinant TLR Proteins and Peptides
Recombinant fusion proteins consisting of the extracellular domains of the
human TLRs TLR9 (amino acids 1–818) and TLR2 (amino acids 1–588) fused
to mouse IgG2b-Fc were constructed by amplifying the corresponding extra-
cellular domain and ligating the fragment in frame into a pCIneo vector contain-
ing the coding sequence for mouse IgG2b-Fc. Fusion proteins were stably
expressed in 293-F cells and purified from cell lysates by protein G affinity
chromatography. Peptides were derived from unique regions of human Tlr9
ectodomain sequence and synthesized by Operon Technologies.
Intraperitoneal Neutrophil Recruitment
sHZ (1000 mg) was resuspended in 200 ml PBS and intraperitoneally adminis-
tered to various mice. At 16–18 hr after injection, the peritoneum was washed
with a 30 ml cold PBS containing EDTA (3 mM) and heparin (10 U/ml) and the
cells were counted. Neutrophils were identified using PE-conjugated anti-Gr-1
and APC-conjugated anti-CD11b antibodies (Becton Dickinson) in the pres-
ence of an anti-CD16 antibody. The stained cells were washed and analyzed
using a FACSCalibur system.
Antibody and Cytokine ELISA
The plates were coated with OVA (1 mg/ml) or HSA (10 mg/ml), Derf2 (1 mg/ml) or
Pf SE36 antigen (3 mg/ml) and analyzed by ELISA using a previously described
procedure (Coban et al., 2005; Okech et al., 2006).
Spleens were extracted 3 weeks after the prime immunization and then stim-
ulated with Pf crude extract. Seventy-two hours later, the cell culture superna-
tants were collected and analyzed for IFNg, IL-13, IL-5, and IL-17 by ELISA
(DuoSet ELISA Kit, R&D Systems).
Binding Assay and ELISA
Zymosan (5 mg/ml), CpG DNA (D35; 10 mg/ml), Pf crude extract (10 mg/ml), and
Pf DNA (2 mg/ml) were coated on 96-well plates in PBS overnight at 4C and
then blocked with PBS containing 1% bovine serum albumin. The binding of
TLR9 or TLR2 fusion proteins was detected with HRP-labeled mouse anti-
IgG (Southern Biotech.). For competition ELISAs, rTLR9 protein was incubated
with sHZ, MSU or CpG DNA for 1 hr and then incubated on Pf crude extract-
coated plates for an additional 1 hr.CellCD Spectroscopy
CD spectra were recorded with a J-820 spectropolarimeter (Jasco) using a
1 mm cell at 20C. Each sample containing 1 mM TLR9 protein with or without
a ligand (1 or 10 mM CpG DNA; 10 or 100 mM sHZ, or 10 or 100 mM MSU),
was prepared in 20 mM sodium acetate buffer containing 150 mM NaCl at
pH 5.5. Twenty spectra were acquired for each sample with a 1 nm bandwidth,
a scanning speed of 50 nm per min, and a response time of 2 s, and then
averaged. The resultant spectra were calculated after the spectra of rTLR9
were subtracted.
NMR Spectroscopy
1H-1D NMR measurements were carried out using an AV400M NMR machine
(Bruker BioSpin, Rheinstetten, Germany) with a 5 mm Shigemi tube (Shigemi,
Tokyo, Japan) at 25C. Each sample was prepared at a peptide concentration
of 250 mM in 20 mM sodium phosphate buffer (pH 7.0) containing 10% (v/v)
D2O for the signal lock. For the measurements with hemin, various concentra-
tions of hemin were prepared and the pH was set to 7.0 to prevent precipitation
of hemin. For the measurements with CpG DNA (D35), because the signals
from CpG DNA were larger than those from the peptides, the spectrum of
D35 was subtracted from the spectra of the peptide-CpG DNA mixture to
more easily judge the difference. All NMR data were processed and analyzed
using NMRPipe (Delaglio et al., 1995) and Igor Pro (WaveMetrics, Lake Os-
wego, OR).
FESEM and Particle Size Analysis
Slides were coated with different dilutions of sHZ and images were captured
using ultra-high-resolution FESEM (S-4800; Hitachi). The particle size and
distribution in the sHZ solution were analyzed using a laser-scattering particle
size distribution analyzer (LA-950; Horiba).
Statistical Analysis
Statistical differences between groups were analyzed using the Student’s
t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at doi:10.1016/j.chom.2009.12.003.
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